Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Olema Pharmaceuticals, Inc. - Common Stock (NQ:OLMA)

6.065 -0.225 (-3.58%)
Streaming Delayed Price Updated: 12:59 PM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Olema Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Second Quarter 2025 Financial and Operating Results
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports First Quarter 2025 Financial and Operating Results
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
From Olema Oncology
Via GlobeNewswire
Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Olema Oncology
Via GlobeNewswire
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
From Olema Oncology
Via GlobeNewswire
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium
Olema will host an investor conference call at 8:00 a.m. ET on December 10, 2024 
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.